Long-term use of Bonviva for the treatment of postmenopausal osteoporosis: new evidence
https://doi.org/10.14412/1996-7012-2012-717
Abstract
Osteoporosis is a disease of great social importance. Its treatment is a complicated problem and it is associated with low compliance and a risk for adverse reactions. Ibandronate belongs to a group of bisphosphonates. The performed trials have proven the efficacy of its two formulations (a tablet once monthly and intravenous injection once every 3 months) in reducing the risk of bone fractures. At present there are data of trials of long-term therapy with this drug, which demonstrate its positive effect on bone mineral density and bone metabolism markers. The agent has been also shown to be highly safe when used long.
References
1. <div><p>Клинические рекомендации по диагностике, лечению и профилактике остеопороза. М., 2008; 176 с.</p><p>Cramer J.A., Gold D.T., Silverman S.L. et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteopor Int 2007; 18: 1023—103.</p><p>Landfeldt E., Strom O., Robbins S. et al. Adherence to treatment of primary osteoporosis and its association to fractures — the Swedish Adherence Register Analysis (SARA). Osteopor Int (in press).</p><p>Emkey R., Koltun W., Beusterien K. et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21(12): 1895—903.</p><p>Hadji P., Minne H., Pfeifer M. et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 2007; 75(3): 303—10.</p><p>Cooper A., Drake J., Brankin E. Investigators PERSIST (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60: 896—905.</p><p>Barrett J., Worth E., Bauss F. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004; 44: 951—65.</p><p>Dando T.M., Noble S. Once-monthly ibandronate. Treat Endocrin 2005; 4(6): 381—7.</p><p>Croom K.F., Scott L.J. Intravenous ibandronate: in the treatment of osteoporosis. Drugs 2006; 66(12): 1593—601.</p><p>Russell R.G., Watts N.B., Ebetino F.H. et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteopor Int 2008; 19(6): 732—59.</p><p>Chesnut 3rd C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241 —9.</p><p>Bachmann G., Barr C.E., Gass M. Ibandronate reduces fracture rates in patients younger than 60 years with low lumbar spine bone mineral density. Obstet Gynecol 2006; 107(Suppl. 4): 82—3.</p><p>Felsenberg D., Miller P., Armbrecht G. et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 2005; 37(5): 651—4.</p><p>Miller P.D., McClung M.R., Macovei L. et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20(8): 1315—22.</p><p>Reginster J.Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: year results from the MOBILE study. Ann Rheum Dis 2006; 65(5): 654—61.</p><p>Miller P.D., Epstein S., Sedarati F. et al. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008; 24(1): 207—13.</p><p>Stakkestad J.A., Lakatos P., Lorenc R. et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheum 2008; 27(8): 955—60.</p><p>Delmas P.D., Adami S., Strugala C. et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthr Rheum 2006; 54(6): 1838—46.</p><p>Eisman J.A., Civitelli R., Adami S. et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheum 2008; 35(3): 488—97.</p><p>Recknor C., Lillestol M., Grant R. et al. Quarterly intravenous ibandronate injections provide continuing benefits in women with postmenopausal osteoporosis: DIVA study long-term extension [abstract no. W363]. J Bone Miner Res 2007; 22(Suppl. 1): 453.</p><p>Bianchi G., Garcia-Hernandez P., Grant R. et al. The DIVA study long-term extension: maintained efficacy with quarterly intravenous ibandronate injection [abstr no. SAT0292]. 2007 Annual European Congress of Rheumatology 2007 Jun 13—16, Barcelona.</p><p>Emkey R., Chesnut 3rd C.H., Schimmer R.C. et al. Benefits of oral ibandronate on non-vertebral fracture risk in postmenopausal osteoporosis: further analyses from a pivotal phase III study [abstract no. T389]. J Bone Miner Res 2007; 22(Suppl. 1): S329.</p><p>Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteopor Rep 2009; 7: 12—7.</p><p>Bone H.G., Hosking D., Devogelaer J.-P. et al. Alendronate Phase III Osteoporosis Treatment Study Group Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189—99.</p><p>Mellstrom D.D., Sorensen O.H., Goemaere S. et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462—8.</p><p>Black D., Reid I., Cauley J. et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON Pivotal Fracture Trial (PFT). J Bone Miner Res 2010; 25(Suppl. 1): 1070. Available at http://www.asbmr.org/Meetings/AnnualMeet ing/AbstractDetail.aspx?aid=4781a020-dc3a-46be-b49d-f706b5509c4eAcces 13 Jan 2011.</p><p>Reginster J.-Y., Rabenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging, 2006; 1: 415—23.</p><p>Reginster J.Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654—61.</p><p>Miller P.D., Recker R.R., Reginster J.Y. et al. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE longterm extension study. Osteopor Int 2011 [Epub ahead of print].</p><p>Delmas P.D., Adami S., Strugala C. et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthr Rheum 2006; 54: 1838—46.</p><p>Bianchi G., Czerwinski E., Kenwright A. et al. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study longterm extension. Osteopor Int 2011 [Epub ahead of print].</p><p>Garnero P., Borel O., Delmas P.D. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001; 47: 694—702.</p><p>Garnero P., Vergnaud P., Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008; 54: 188—96.</p></div><br />
Review
For citations:
Yershova OB, Belova KY, Nazarova AV. Long-term use of Bonviva for the treatment of postmenopausal osteoporosis: new evidence. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2012;6(1):57-60. (In Russ.) https://doi.org/10.14412/1996-7012-2012-717
Views:
2967
Email this article 